



NDA 20297/S-037

**SUPPLEMENT APPROVAL**

SmithKline Beecham (Cork) Ltd.  
c/o GlaxoSmithKline  
Attention: Ms. Linda Rebar  
Director, Global Regulatory Affairs  
2301 Renaissance Blvd., RN0420, P.O. Box 61540  
King of Prussia, PA 19406-2772

Dear Ms. Rebar:

Please refer to your Supplemental New Drug Application (sNDA) dated April 1, 2015, received April 1, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for COREG<sup>®</sup> (carvedilol) Tablets, 3.125, 6.25, 12.5, and 25 mg.

This Prior Approval supplemental new drug application proposes to revise the “Overdosage” section (Section 10) by removing the statement “gastric lavage or pharmacologically induced emesis may be used shortly after ingestion”.

**APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revisions listed below and indicated in the enclosed labeling.

- Addition of the route of administration (for oral use) as required by 21 CFR 201.57(a)(2)

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to, except with the revisions listed and indicated, the enclosed labeling (text for the package insert) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes with the revisions listed and indicated above approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact Sabry Soukehal, Consumer Safety Officer at (240) 402 6187.

Sincerely,

{ See appended electronic signature page }

Norman Stockbridge, MD, PhD  
Director  
Division of Cardiovascular and Renal Products  
Office of Drug Evaluation 1  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

NORMAN L STOCKBRIDGE  
10/02/2015